Shanghai Team Cracks Code on Rare Facial Disorder

Children and adults with facial infiltrating lipomatosis have long suffered without answers, but a medical team in Shanghai just changed that.

Dr. Lin Xiaoxi and researchers at Shanghai Ninth People's Hospital have identified what causes this rare congenital disorder, where fat cells abnormally multiply and invade facial muscles, soft tissue, and sometimes bone. Unlike typical growths, these never shrink on their own.

The condition goes far beyond appearance. Patients struggle to eat, swallow, see, and even breathe as their faces grow increasingly asymmetric. The physical challenges come alongside crushing psychological weight.

Lin's team didn't just identify the cause. They developed targeted therapies and refined plastic surgery techniques to restore both function and appearance. Their research, published in the prestigious journal Advanced Science, has already shaped 13 international medical guidelines.

The hospital created the world's first dedicated database for this condition, giving future researchers a foundation that never existed before. With over 36,000 vascular malformation patients treated annually, the team sees cases other hospitals can't handle.

The Ripple Effect

The Shanghai breakthrough extends beyond one rare disorder. The same team is pioneering China's first clinical trial for a targeted drug treating extracranial arteriovenous malformations, where arteries connect directly to veins and bypass normal blood flow. This high-risk condition causes severe tissue disfigurement and has traditionally required dangerous, invasive procedures.

The new drug shows remarkable promise. After just 16 weeks of treatment, many patients saw their lesions shrink by more than half. The trial recently expanded age eligibility from 12 to 70 years, opening doors for children and older adults who previously had no options.

Medical foundations in the United States and Europe now regularly refer their most complex cases to Shanghai Ninth People's Hospital. What started as local research has become an internationally recognized standard of care, earning the team recognition at the 2025 International Society for the Study of Vascular Anomalies meeting in Paris.

Patients worldwide finally have a roadmap forward, backed by science that turns devastating diagnoses into treatable conditions.